TORONTO and WINNIPEG, Dec. 18 /CNW/ - Cangene Corporation today reports that it has received a positive opinion from the EMA’s Committee for Medicinal Products for Human Use (“CHMP”) regarding the immunoprophylaxis indication of Cangene’s ImmunoGam(TM) (Human Hepatitis B Immunoglobulin). This is the product marketed as HepaGam B(R) in North America and Israel, and is a hyperimmune antibody product containing antibodies specific for the hepatitis B surface antigen. A Marketing Authorization from The European Commission should follow within 67 days following adoption of the opinion.
